Signature for Precise Chemosensitivity Prediction in PDAC

Shanghai Jiao Tong University

Status: Completed

Conditions: Pancreatic Cancer

Treatments: Drug: Chemotherapy

Study type: Observational

Funder types: Other

Identifiers

NCT06461598

ChemoResist-01

Details and patient eligibility

About

Pancreatic ductal adenocarcinoma (PDAC) is largely heterogeneous. We sought to develop and validate a signature to precisely predict chemotherapy sensitivity in PDAC. Genetic events of the four most commonly mutated genes in PDAC and expressions of 12 PI3K/AKT/mTOR pathway markers were examined in consecutive patients with PDAC. A 9-feature signature for prediction of chemotherapy benefits was constructed using the LASSO Cox regression model, and validated in two independent cohorts.

Enrollment: 365 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• ECOG performance status score of 0-1 before resection
• complete clinicopathologic and follow-up data
• availability of formalin-fixed paraffin-embedded (FFPE) specimens of resected primary tumor and hematoxylin and eosin slides with invasive tumor components

Exclusion criteria

• any previous history of cancer
• any anticancer therapy prior to resection or adjuvant radiotherapy
• metastatic cases
• major postsurgical complications with Clavien-Dindo Grade ≥2

Trial design

365 participants in 2 patient groups

Training cohort

Treatment:

Drug: Chemotherapy

Validation cohort

Treatment:

Drug: Chemotherapy